authors
- Orkin C
- Petrovic R
- Vanveggel S
- Opsomer M
- GUTIERREZ RODERO, FELIX
- Molina JM
- Negredo E
- Arribas JR
- Gathe J
- Eron JJ
- Van Landuyt E
- Lathouwers E
- Hufkens V
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial
Academic Article
2018
- Overview
- Otro
- Ver todos